BioSpace News Archive

SAWC – Kerecis® announced MariGen® Shield, which integrates the company’s proven fish-skin graft with a silicone contact layer for treating chronic and complex wounds.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2022 and provided an update on key clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2023 Company’s outlook.

Ovid Therapeutics Inc. reports that Takeda Pharmaceuticals presented interim data at the 2023 annual meeting of the American Academy of Neurology from ENDYMION 1, a long-term, open label extension study evaluating the effects of soticlestat on patients with Dravet syndrome and Lennox-Gastaut syndrome.

Avidity Biosciences, Inc. announced positive topline data from the Phase 1/2 MARINA™ clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1 demonstrating functional improvement, DMPK reduction, splicing improvements and a favorable safety and tolerability profile.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced the presentation of key data from its Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010 at the ARVO annual meeting.

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2023 financial results and corporate highlights after the close of market on Thursday, May 4, 2023.

Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.

Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market closes.

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”) today announced that it will release its first quarter 2023 financial results after the market closes on Thursday, May 11, 2023, via press release, which will be available on the Company’s website at https://ir.nrxpharma.com/.